Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: June 2013

Cervical and Ovarian Cancers and Impact New Data – 3rd MDoutlook OncoPoll™ from ASCO

Oncology Intelligence Delivered: MDoutlook® has released its 3rd OncoPoll™ report from ASCO 2013, covering cervical and ovarian cancers.

This latest research yields important insight:
* New information on the dosing schedule for 1st line chemotherapy in ovarian cancer is considered important and will be integrated into clinical practice immediately
* Pazopanib maintenance therapy is expected to increase 5-fold in advanced ovarian cancer
* Large increase in the usage of bevacizumab with chemotherapy will be seen in cases of advanced cervical cancer.

You can download the OncoPoll ASCO 2013 – Gynecological Cancers here.

This is the third of four surveys – launched directly following ASCO – in which we have pulsed our global network of 75,000 verified and validated cancer treaters to assess the value and impact on daily cancer management of new clinical and research data presented. MDoutlook is the first disease intelligence organization to publish on the clinical impact of new data released at the annual American Society of Clinical Oncology meeting, held June 1-4, 2013 in Chicago. We are collaborating with Oncology Business Review to disseminate this important research to the widest audience.

MDoutlook is disease intelligence redefined:
Governed by ThoughtLeaders
– Driven by in-house disease experts
– Powered by access to proprietary network of treaters

Contact us to discuss how MDoutlook can drive your disease intelligence needs: by email or phone (+1.404.496.4136; 888.3outlook).

Significant Change in GI Cancer Management Expected – 2nd MDoutlook OncoPoll™ from ASCO

Oncology Intelligence Delivered: MDoutlook is proud to present the latest ASCO OncoPoll™ report, focused on colorectal, pancreatic and other gastrointestinal cancers.

The MDoutlook ASCO 2013 OncoPoll™ – GI Cancers report provides a number of important observations from our research:
* Cetuximab: significant increase expected in first line use mCRC treatment
* Bevacizumab: 25% of oncologists expect increase in usage in maintenance treatment of mCRC
* Abraxane: close to half of patients with metastatic Pancreatic Cancer are expected to receive Abraxane as treatment upon approval. Most physicians expect approval of Abraxane in this indication

With four surveys – launched directly following ASCO – we have pulsed our global network of 75,000 verified and validated cancer treaters to assess the value and impact on daily cancer management of new clinical and research data presented. MDoutlook is the first disease intelligence organization to publish on the clinical impact of new data released at the annual American Society of Clinical Oncology meeting, held June 1-4, 2013 in Chicago. And continue to work with Oncology Business Review (OBR) to ensure maximum distribution of this report.

MDoutlook is disease intelligence redefined:
Governed by ThoughtLeaders
– Driven by in-house disease experts
– Powered by access to proprietary network of treaters

If you would like to discuss how MDoutlook can support your disease intelligence needs, please contact us by email or phone (+1.404.496.4136; 888.3outlook).

Regards,
Jan Heybroek
President, MDoutlook

MDoutlook ASCO OncoPoll™ released – New Data in Thyroid Cancer Has Important Clinical Impact

Pursuing our tradition for the 6th year, MDoutlook is the first disease intelligence organization to publish on the clinical impact of new data released at the annual American Society of Clinical Oncology meeting, held June 1-4, 2013 in Chicago.

Collaborating with our global network of 75,000+ cancer treaters, we have already received more than 300 completed surveys from 23 countries less than 10 days after the meeting. Through four surveys – launched directly following ASCO – we pulse our network of verified and validated physicians to assess the value and impact on daily cancer management of new clinical and research data presented.

Focusing on key new data presented in Thyroid, GastroIntestinal (focus on CRC) and Gynecological Cancers and new immunotherapeutics, we will be distributing the results in 4 reports.

The new clinical data presented has significant clinical impact according to the 96 thyroid cancer experts responding to our OncoPoll. This report has the details and is the first of a series of four to be released in the next few weeks: MDoutlook ASCO OncoPoll 2013 – Thyroid Cancer.

We thank all physicians and other professionals involved for working closely to make this well-received series of reports a reality. We also continue to work with our friends at Oncology Business Review (OBR) to ensure maximum distribution of this report; their Editor’s Blog has a copy of the results.

MDoutlook is disease intelligence redefined:
•Governed by ThoughtLeaders
•Driven by in-house disease experts
•Powered by access to proprietary network of treaters

Our post-ASCO OncoPolls™ have generated responses from more than 2,500 cancer treaters in 44 countries over the last 6 years, with insight delivered within 5 business days from fielding.

If you have any questions or would like to discuss how MDoutlook can support your disease intelligence needs, please contact us directly.

Regards,
Jan Heybroek
President, MDoutlook

At the recent annual ASCO meeting in Chicago we received the highest compliment from a client you can expect: we were awarded “Best Practice” for a ThoughtLeader identification and mapping project that we completed earlier in the year.

This compliment was bestowed upon us by the European headquarters of a US-based major, leading pharmaceutical company with a long presence in oncology. The project was focused on a new and exciting research area within oncology.

Some samples from our report are shown below. The network visualization and especially our exclusive and unique MDoutlook ThoughtLeader Attribute Dial™ are highly appreciated by our clients.

Contact us by email or via the contact form for more information or a proposal in your interest area.

MDoutlook ThoughtLeader Dashboard - Exclusive Attribute Dial

MDoutlook ThoughtLeader Dashboard – Exclusive Attribute Dial

MDoutlook TL Dashboard - Professional Network Visualization

MDoutlook TL Dashboard – Professional Network Visualization